JavaScript is disabled for your browser. Some features of this site may not work without it.
Statistics
Total Visits
| Views | |
|---|---|
| Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial | 100 |
Total Visits Per Month
| January 2024 | February 2024 | March 2024 | April 2024 | May 2024 | June 2024 | July 2024 | |
|---|---|---|---|---|---|---|---|
| Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial | 10 | 3 | 3 | 3 | 6 | 6 | 2 |
Top country views
| Views |
|---|
Top cities views
| Views |
|---|
